Hyku Biosciences is developing the next generation of small molecule medicines by targeting histidine, tyrosine
#5 of 55 therapeutics startups
▲ 1 since the last ranking
Ranked 6:02 AM PT · Thu, Nov 19
Established
Hyku Biosciences is developing the next generation of small molecule medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
If a fact is wrong, or you want the profile removed, tell us: we act on every request within 2 business days.